APO Research
Talk to an analyst

APO RESEARCH · REPORT

Women’s Health Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Women’s Health Drugs Industry Growth and Trends Forecast to 2032

31 December 2025103 pages

Choose your research edition.

Industry ResearchWomen’s Health Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Women’s Health Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Women’s Health Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Women’s Health Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Women’s Health Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

According to APO Research, the global Women’s Health Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Women’s Health Drugs market include Johnson & Johnson, Novartis AG, Merck & Co, Mylan N.V., Pfizer Inc, Bayer AG, Amgen, Lupin (India) and Ferring Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Women’s Health Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Women’s Health Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Women’s Health Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Women’s Health Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Women’s Health Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Women’s Health Drugs Market by Company

Johnson & Johnson

Novartis AG

Merck & Co

Mylan N.V.

Pfizer Inc

Bayer AG

Amgen

Lupin (India)

Ferring Pharmaceuticals

Eli Lilly And Company

Allergan

Agile Therapeutics Inc

Women’s Health Drugs Segment by Type

Minastrin 24 Fe

XGEVA

Prolia

Mirena

EVISTA

Zometa

Reclast/Aclasta

Others (Premarin, ACTONEL, ORTHO TRI-CY LO)

Women’s Health Drugs Segment by Application

Contraceptives

Polycystic Ovary Syndrome

Hormonal Infertility

Menopause

Postmenopausal Osteoporosis

Endometriosis

Other Applications

Women’s Health Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women’s Health Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Women’s Health Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women’s Health Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Women’s Health Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Women’s Health Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Women’s Health Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Women’s Health Drugs Market Share by Region (2021-2026) Table 4. Global Women’s Health Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Women’s Health Drugs Market Share by Region (2027-2032) Table 6. Global Women’s Health Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Women’s Health Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Women’s Health Drugs Market Size Share by Type (2021-2026) Table 9. Global Women’s Health Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Women’s Health Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Women’s Health Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Women’s Health Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Women’s Health Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Women’s Health Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Women’s Health Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Women’s Health Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Women’s Health Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Women’s Health Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Women’s Health Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Women’s Health Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Women’s Health Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Women’s Health Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Women’s Health Drugs Market Size Share by Application (2021-2026) Table 24. Global Women’s Health Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Women’s Health Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Women’s Health Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Women’s Health Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Women’s Health Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Women’s Health Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Women’s Health Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Women’s Health Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Women’s Health Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Women’s Health Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Women’s Health Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Women’s Health Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Women’s Health Drugs Industry Trends Table 37. Women’s Health Drugs Industry Drivers Table 38. Women’s Health Drugs Industry Opportunities and Challenges Table 39. Women’s Health Drugs Industry Restraints Table 40. Global Women’s Health Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Women’s Health Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Women’s Health Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Women’s Health Drugs Key Company Headquarters & Area Served Table 44. Global Women’s Health Drugs Company, Product Type & Application Table 45. Global Women’s Health Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Women’s Health Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Women’s Health Drugs Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Novartis AG Company Information Table 54. Novartis AG Business Overview Table 55. Novartis AG Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis AG Women’s Health Drugs Product Portfolio Table 57. Novartis AG Recent Development Table 58. Merck & Co Company Information Table 59. Merck & Co Business Overview Table 60. Merck & Co Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Merck & Co Women’s Health Drugs Product Portfolio Table 62. Merck & Co Recent Development Table 63. Mylan N.V. Company Information Table 64. Mylan N.V. Business Overview Table 65. Mylan N.V. Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Mylan N.V. Women’s Health Drugs Product Portfolio Table 67. Mylan N.V. Recent Development Table 68. Pfizer Inc Company Information Table 69. Pfizer Inc Business Overview Table 70. Pfizer Inc Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Pfizer Inc Women’s Health Drugs Product Portfolio Table 72. Pfizer Inc Recent Development Table 73. Bayer AG Company Information Table 74. Bayer AG Business Overview Table 75. Bayer AG Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Bayer AG Women’s Health Drugs Product Portfolio Table 77. Bayer AG Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Amgen Women’s Health Drugs Product Portfolio Table 82. Amgen Recent Development Table 83. Lupin (India) Company Information Table 84. Lupin (India) Business Overview Table 85. Lupin (India) Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Lupin (India) Women’s Health Drugs Product Portfolio Table 87. Lupin (India) Recent Development Table 88. Ferring Pharmaceuticals Company Information Table 89. Ferring Pharmaceuticals Business Overview Table 90. Ferring Pharmaceuticals Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Ferring Pharmaceuticals Women’s Health Drugs Product Portfolio Table 92. Ferring Pharmaceuticals Recent Development Table 93. Eli Lilly And Company Company Information Table 94. Eli Lilly And Company Business Overview Table 95. Eli Lilly And Company Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Eli Lilly And Company Women’s Health Drugs Product Portfolio Table 97. Eli Lilly And Company Recent Development Table 98. Allergan Company Information Table 99. Allergan Business Overview Table 100. Allergan Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Allergan Women’s Health Drugs Product Portfolio Table 102. Allergan Recent Development Table 103. Agile Therapeutics Inc Company Information Table 104. Agile Therapeutics Inc Business Overview Table 105. Agile Therapeutics Inc Women’s Health Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Agile Therapeutics Inc Women’s Health Drugs Product Portfolio Table 107. Agile Therapeutics Inc Recent Development Table 108. North America Women’s Health Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Women’s Health Drugs Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Women’s Health Drugs Market Share by Country (2021-2026) Table 111. North America Women’s Health Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Women’s Health Drugs Market Share Forecast by Country (2027-2032) Table 113. Europe Women’s Health Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Women’s Health Drugs Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Women’s Health Drugs Market Share by Country (2021-2026) Table 116. Europe Women’s Health Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Women’s Health Drugs Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Women’s Health Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Women’s Health Drugs Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Women’s Health Drugs Market Share by Country (2021-2026) Table 121. Asia-Pacific Women’s Health Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Women’s Health Drugs Market Share Forecast by Country (2027-2032) Table 123. Latin America Women’s Health Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Women’s Health Drugs Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Women’s Health Drugs Market Share by Country (2021-2026) Table 126. Latin America Women’s Health Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Women’s Health Drugs Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Women’s Health Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Women’s Health Drugs Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Women’s Health Drugs Market Share by Country (2021-2026) Table 131. Middle East & Africa Women’s Health Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Women’s Health Drugs Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Women’s Health Drugs Product Image Figure 3. Global Women’s Health Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Women’s Health Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Women’s Health Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Women’s Health Drugs Market Share by Region (2021-2032) Figure 7. North America Women’s Health Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Women’s Health Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Women’s Health Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Women’s Health Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Women’s Health Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Minastrin 24 Fe Image Figure 13. Global Minastrin 24 Fe Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. XGEVA Image Figure 15. Global XGEVA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Prolia Image Figure 17. Global Prolia Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Mirena Image Figure 19. Global Mirena Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. EVISTA Image Figure 21. Global EVISTA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Zometa Image Figure 23. Global Zometa Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Reclast/Aclasta Image Figure 25. Global Reclast/Aclasta Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Others (Premarin, ACTONEL, ORTHO TRI-CY LO) Image Figure 27. Global Others (Premarin, ACTONEL, ORTHO TRI-CY LO) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Global Women’s Health Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 29. Global Women’s Health Drugs Market Share by Type 2025 VS 2032 Figure 30. North America Women’s Health Drugs Market Size Share by Type (2021-2032) Figure 31. Europe Women’s Health Drugs Market Size Share by Type (2021-2032) Figure 32. Asia-Pacific Women’s Health Drugs Market Size Share by Type (2021-2032) Figure 33. Latin America Women’s Health Drugs Market Size Share by Type (2021-2032) Figure 34. Middle East and Africa Women’s Health Drugs Market Size Share by Type (2021-2032) Figure 35. Contraceptives Image Figure 36. Global Contraceptives Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Polycystic Ovary Syndrome Image Figure 38. Global Polycystic Ovary Syndrome Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Hormonal Infertility Image Figure 40. Global Hormonal Infertility Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Menopause Image Figure 42. Global Menopause Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. Postmenopausal Osteoporosis Image Figure 44. Global Postmenopausal Osteoporosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Endometriosis Image Figure 46. Global Endometriosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. Other Applications Image Figure 48. Global Other Applications Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Global Women’s Health Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 50. Global Women’s Health Drugs Market Share by Application 2025 VS 2032 Figure 51. North America Women’s Health Drugs Market Size Share by Application (2021-2032) Figure 52. Europe Women’s Health Drugs Market Size Share by Application (2021-2032) Figure 53. Asia-Pacific Women’s Health Drugs Market Size Share by Application (2021-2032) Figure 54. Latin America Women’s Health Drugs Market Size Share by Application (2021-2032) Figure 55. Middle East and Africa Women’s Health Drugs Market Size Share by Application (2021-2032) Figure 56. Global Top 5 and 10 Women’s Health Drugs Players Market Share by Revenue in 2025 Figure 57. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 58. North America Women’s Health Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. North America Women’s Health Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. North America Women’s Health Drugs Market Share by Country (2021-2032) Figure 61. Europe Women’s Health Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Europe Women’s Health Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Women’s Health Drugs Market Share by Country (2021-2032) Figure 64. Asia-Pacific Women’s Health Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 65. Asia-Pacific Women’s Health Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Women’s Health Drugs Market Share by Country (2021-2032) Figure 67. Latin America Women’s Health Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Women’s Health Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Latin America Women’s Health Drugs Market Share by Country (2021-2032) Figure 70. Middle East & Africa Women’s Health Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 71. Middle East & Africa Women’s Health Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 72. Middle East & Africa Women’s Health Drugs Market Share by Country (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Minastrin 24 Fe
  • XGEVA
  • Prolia
  • Mirena
  • EVISTA
  • Zometa
  • Reclast/Aclasta
  • Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
Applications
  • Contraceptives
  • Polycystic Ovary Syndrome
  • Hormonal Infertility
  • Menopause
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Other Applications
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co
  • Mylan N.V.
  • Pfizer Inc
  • Bayer AG
  • Amgen
  • Lupin (India)
  • Ferring Pharmaceuticals
  • Eli Lilly And Company
  • Allergan
  • Agile Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Women’s Health Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Women’s Health Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Women’s Health Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Women’s Health Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Women’s Health Drugs Market Size (2021-2032)
  8. 1.5.1 North America Women’s Health Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Women’s Health Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Women’s Health Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Women’s Health Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Women’s Health Drugs Market Size Growth Rate (2021-2032)
2 Women’s Health Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Minastrin 24 Fe
  3. 2.1.2 XGEVA
  4. 2.1.3 Prolia
  5. 2.1.4 Mirena
  6. 2.1.5 EVISTA
  7. 2.1.6 Zometa
  8. 2.1.7 Reclast/Aclasta
  9. 2.1.8 Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
  10. 2.2 Global Women’s Health Drugs Market Size by Type
  11. 2.2.1 Global Women’s Health Drugs Market Size Overview by Type (2021-2032)
  12. 2.2.2 Global Women’s Health Drugs Historic Market Size Review by Type (2021-2026)
  13. 2.2.3 Global Women’s Health Drugs Market Size Forecasted by Type (2027-2032)
  14. 2.3 Global Women’s Health Drugs Market Size by Regions
  15. 2.3.1 North America Women’s Health Drugs Market Size Breakdown by Type (2021-2026)
  16. 2.3.2 Europe Women’s Health Drugs Market Size Breakdown by Type (2021-2026)
  17. 2.3.3 Asia-Pacific Women’s Health Drugs Market Size Breakdown by Type (2021-2026)
  18. 2.3.4 South America Women’s Health Drugs Market Size Breakdown by Type (2021-2026)
  19. 2.3.5 Middle East and Africa Women’s Health Drugs Market Size Breakdown by Type (2021-2026)
3 Women’s Health Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Contraceptives
  3. 3.1.2 Polycystic Ovary Syndrome
  4. 3.1.3 Hormonal Infertility
  5. 3.1.4 Menopause
  6. 3.1.5 Postmenopausal Osteoporosis
  7. 3.1.6 Endometriosis
  8. 3.1.7 Other Applications
  9. 3.2 Global Women’s Health Drugs Market Size by Application
  10. 3.2.1 Global Women’s Health Drugs Market Size Overview by Application (2021-2032)
  11. 3.2.2 Global Women’s Health Drugs Historic Market Size Review by Application (2021-2026)
  12. 3.2.3 Global Women’s Health Drugs Market Size Forecasted by Application (2027-2032)
  13. 3.3 Global Women’s Health Drugs Market Size by Regions
  14. 3.3.1 North America Women’s Health Drugs Market Size Breakdown by Application (2021-2026)
  15. 3.3.2 Europe Women’s Health Drugs Market Size Breakdown by Application (2021-2026)
  16. 3.3.3 Asia-Pacific Women’s Health Drugs Market Size Breakdown by Application (2021-2026)
  17. 3.3.4 South America Women’s Health Drugs Market Size Breakdown by Application (2021-2026)
  18. 3.3.5 Middle East and Africa Women’s Health Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Women’s Health Drugs Industry Trends
  2. 4.2 Women’s Health Drugs Industry Drivers
  3. 4.3 Women’s Health Drugs Industry Opportunities and Challenges
  4. 4.4 Women’s Health Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Women’s Health Drugs Revenue (2021-2026)
  2. 5.2 Global Women’s Health Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Women’s Health Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Women’s Health Drugs Company, Product Type & Application
  5. 5.5 Global Women’s Health Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Women’s Health Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Women’s Health Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Women’s Health Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Women’s Health Drugs Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis AG Women’s Health Drugs Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Merck & Co
  14. 6.3.1 Merck & Co Company Information
  15. 6.3.2 Merck & Co Business Overview
  16. 6.3.3 Merck & Co Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Merck & Co Women’s Health Drugs Product Portfolio
  18. 6.3.5 Merck & Co Recent Developments
  19. 6.4 Mylan N.V.
  20. 6.4.1 Mylan N.V. Company Information
  21. 6.4.2 Mylan N.V. Business Overview
  22. 6.4.3 Mylan N.V. Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Mylan N.V. Women’s Health Drugs Product Portfolio
  24. 6.4.5 Mylan N.V. Recent Developments
  25. 6.5 Pfizer Inc
  26. 6.5.1 Pfizer Inc Company Information
  27. 6.5.2 Pfizer Inc Business Overview
  28. 6.5.3 Pfizer Inc Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Inc Women’s Health Drugs Product Portfolio
  30. 6.5.5 Pfizer Inc Recent Developments
  31. 6.6 Bayer AG
  32. 6.6.1 Bayer AG Company Information
  33. 6.6.2 Bayer AG Business Overview
  34. 6.6.3 Bayer AG Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Bayer AG Women’s Health Drugs Product Portfolio
  36. 6.6.5 Bayer AG Recent Developments
  37. 6.7 Amgen
  38. 6.7.1 Amgen Company Information
  39. 6.7.2 Amgen Business Overview
  40. 6.7.3 Amgen Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Amgen Women’s Health Drugs Product Portfolio
  42. 6.7.5 Amgen Recent Developments
  43. 6.8 Lupin (India)
  44. 6.8.1 Lupin (India) Company Information
  45. 6.8.2 Lupin (India) Business Overview
  46. 6.8.3 Lupin (India) Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Lupin (India) Women’s Health Drugs Product Portfolio
  48. 6.8.5 Lupin (India) Recent Developments
  49. 6.9 Ferring Pharmaceuticals
  50. 6.9.1 Ferring Pharmaceuticals Company Information
  51. 6.9.2 Ferring Pharmaceuticals Business Overview
  52. 6.9.3 Ferring Pharmaceuticals Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Ferring Pharmaceuticals Women’s Health Drugs Product Portfolio
  54. 6.9.5 Ferring Pharmaceuticals Recent Developments
  55. 6.10 Eli Lilly And Company
  56. 6.10.1 Eli Lilly And Company Company Information
  57. 6.10.2 Eli Lilly And Company Business Overview
  58. 6.10.3 Eli Lilly And Company Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly And Company Women’s Health Drugs Product Portfolio
  60. 6.10.5 Eli Lilly And Company Recent Developments
  61. 6.11 Allergan
  62. 6.11.1 Allergan Company Information
  63. 6.11.2 Allergan Business Overview
  64. 6.11.3 Allergan Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Allergan Women’s Health Drugs Product Portfolio
  66. 6.11.5 Allergan Recent Developments
  67. 6.12 Agile Therapeutics Inc
  68. 6.12.1 Agile Therapeutics Inc Company Information
  69. 6.12.2 Agile Therapeutics Inc Business Overview
  70. 6.12.3 Agile Therapeutics Inc Women’s Health Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Agile Therapeutics Inc Women’s Health Drugs Product Portfolio
  72. 6.12.5 Agile Therapeutics Inc Recent Developments
7 North America
  1. 7.1 North America Women’s Health Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Women’s Health Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Women’s Health Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Women’s Health Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Women’s Health Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Women’s Health Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Women’s Health Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Women’s Health Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Women’s Health Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Women’s Health Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Women’s Health Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Women’s Health Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Women’s Health Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Women’s Health Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Women’s Health Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst